Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05164614 | Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule | PHASE1 | COMPLETED | 50 | — | — | Feb 1, 2022 | Oct 1, 2022 | Oct 30, 2022 | - | — |
| Name | Type | Description |
|---|---|---|
| RT-102 (80 μg) | COMBINATION_PRODUCT | RaniPill capsule containing PTH with doses of 20 and 80 μg |
| Forteo | DRUG | A commercial formulation of PTH for SC control (20 µg) |
| RT-102 (20 μg) | COMBINATION_PRODUCT | RaniPill capsule containing PTH with dose of 20μg |